Brain Neprilysin Activity and Susceptibility to Transgene-Induced Alzheimer Amyloids by Carter, Troy L. et al.
Thomas Jefferson University
Jefferson Digital Commons
Department of Neurology Faculty Papers Department of Neurology
August 2005
Brain Neprilysin Activity and Susceptibility to
Transgene-Induced Alzheimer Amyloids
Troy L. Carter
Thomas Jefferson University
Steve Pedrini
Thomas Jefferson University
Jorge Ghiso
NYU School of Medicine
Michelle E. Ehrlich
Thomas Jefferson University
Sam Gandy
Thomas Jefferson University, samgandy@earthlink.net
Let us know how access to this document benefits you
Follow this and additional works at: http://jdc.jefferson.edu/neurologyfp
Part of the Neurology Commons
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas
Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly
publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and
interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in
Department of Neurology Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact:
JeffersonDigitalCommons@jefferson.edu.
Recommended Citation
Carter, Troy L.; Pedrini, Steve ; Ghiso, Jorge; Ehrlich, Michelle E. ; and Gandy, Sam , "Brain
Neprilysin Activity and Susceptibility to Transgene-Induced Alzheimer Amyloids" (2005).
Department of Neurology Faculty Papers. Paper 2.
http://jdc.jefferson.edu/neurologyfp/2
  Carter et al., Neprilysin and Amyloidosis  
                                                                         8/9/05 version, 11:04 PM 
  1 
 
Brain Neprilysin Activity and Susceptibility to  
Transgene-Induced Alzheimer Amyloidosis 
 
Troy L.Carter, Ph.D.,1,2* Steve Pedrini, Ph.D.,1* Jorge Ghiso, Ph.D.3,  
 
Michelle E. Ehrlich, M.D.,1,2  and Sam Gandy, M.D., Ph.D.1,2,4 
 
 
1Farber Institute for Neurosciences, Thomas Jefferson University, Philadelphia PA 19107  
 
2Lankenau Institute for Medical Research, Wynnewood PA 19096 
 
3Department of Pathology, NYU School of Medicine, New York NY 10016 
 
 
4To whom correspondence should be addressed  
 Sam Gandy, M.D., Ph.D. 
 Farber Institute for Neurosciences of Thomas Jefferson University  
 Jefferson Hospital For Neuroscience 
 900 Walnut Street, Suite 400 
 Philadelphia, PA 19107 
 Ph: 215-503-4200; Fax: 215-503-4358 
 E-mail: samgandy@earthlink.net 
 
*These authors contributed equally. 
 
Running Title: Neprilysin and Amyloidosis 
 
Reference: 34 
Figures: 2 
Title: 9 words 
Abstract: 200 words 
Text: 2570 words 
* Manuscript
  Carter et al., Neprilysin and Amyloidosis  
                                                                         8/9/05 version, 11:04 PM 
  2 
ABSTRACT 
 
Neprilysin (NEP) is a zinc metalloproteinase that degrades enkephalins, endothelins, and 
the Alzheimer’s disease amyloid β (Aβ) peptides.  NEP-deficient mice possess increased 
levels of brain Aβ1-40 and Aβ1-42.  The objective of this study was to determine whether 
tissue NEP specific activity differs according to age and/or across mouse strains, 
especially those strains predisposed toward formation of Aβ-amyloid plaques following 
overexpression of the human Alzheimer amyloid precursor protein (APP). The C57Bl/6J 
mouse strain appears to be relatively susceptible to cerebral amyloidosis, whereas the 
Swiss Webster (SW) strain appears more resistant.  We investigated whether NEP 
specific activity in brain and kidney homogenates from SW and C57 mice of 6, 40, and 
80 weeks old varied according to mouse strain, age, and gender.  Among the variables 
tested, NEP specific activity varied most dramatically across mouse strain, with the 
kidney and brain of SW mice displaying the highest activities.  Aging was associated 
with a reduction in brain NEP specific activity in both strains.  Gender-specific 
differences were identified in kidney but not in brain.  We conclude that aging- and 
strain-dependent differences in NEP specific activity may play a role in the differential 
susceptibility of some mouse strains for developing cerebral amyloidosis following 
human APP overexpression. 
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INTRODUCTION 
 
Alzheimer’s disease (AD) is a progressive neurodegenerative disease characterized by the 
accumulation of senile plaques and neurofibrillary tangles in the brain [1]. The senile 
plaques are composed of amyloid-β peptides (Aβ; Aβ1−40 and Aβ1−42) that are generated 
by the sequential enzymatic cleavage of the amyloid precursor protein by β- and γ-
secretases [for review, see 9].  Aβ deposition is associated with dysfunction and/or death 
of neurons in the human central nervous system, leading to deterioration of memory and 
higher cognitive function [29]. Research toward developing treatments for AD are 
focused on preventing the formation of the Aβ via development of  β- and γ-secretase 
inhibitors or strategies for directly antagonizing Aβ accumulation, using either “plaque-
buster” drugs or immunotherapy to aid in clearing the brain of plaques [reviewed in 9]. 
Another potential therapeutic target focuses on activation of specific proteases that 
metabolize Aβ peptides, thereby clearing them from the brain.  Candidate proteases 
included insulin degrading enzyme (IDE) [30, 33] and neprilysin (NEP) [17].  
 
Neprilysin (NEP) is a 97 kDa type II transmembrane zinc-metalloproteinase that is also 
known as neutral endopeptidase, enkephalinase, EC 3.4.24.11, CD10, and common acute 
lymphoblastic leukemia antigen [6,16].  NEP is expressed in the mammalian CNS and 
peripheral tissues, including kidney, lung, and reproductive organs [6 15, 16].  
Structurally, NEP is a type II transmembrane protein, displaying a long extracellular 
domain that contains the catalytic site, an intramembranous domain, and a short N-
terminal intracellular domain. By virtue of this structure, NEP acts as an ectoenzyme, 
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catalyzing cleavage in the extracellular space [25].  Recently, NEP has drawn much 
attention because of its ability to degrade Aβ40 and Aβ42 in vitro and in vivo [13, 17, 27, 
28, 32], cleaving the Aβ1-42 peptide between the Glu3-Phe4, Gly9-Trp10, Phe19-Phe20, 
Ala30-Ile31, Gly33-Leu34 [13] or Gly37-Gly38 [17] peptide bonds.   Injection of NEP 
inhibitors into the mouse brain results in an accumulation of Aβ peptides [17, 25], and 
transgene-induced overexpression of NEP decreases Aβ levels and plaque load [24]. 
Additionally, NEP knockout mice show increased levels of both Aβ40 and Aβ42 
peptides [26].   
 
In the current study, we sought to test further the hypothesis that alterations in 
endogenous NEP specific activity might be modulated by age, gender [3, 18] and/or 
strain, and that modulation of NEP specific activity as a function of these variables might 
contribute to differential brain Aβ  deposition following overexpression of human APP in 
transgenic mice. 
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MATERIALS AND METHODS 
Reagents 
Phosphoramidon, enalapril and the fluorogenic substrate N-dansyl-D-Ala-Gly-p-nitro-
Phe-Gly were purchased from Sigma (St. Louis, MO, USA)[6,7,12]. Recombinant human 
neprilysin (rhNEP) [14] was purchased from R&D (Minneapolis, MN, USA). 
Phosphoramidon and enalapril were dissolved in water; the substrate peptide was 
dissolved in methanol and then brought to 2 mM with Tris (50 mM, pH 7.4).  
 
Preparation of Kidney and Brain Homogenates 
Mice derived from the Swiss Webster (SW; 6 wk old mice from Charles River; 40 wk old 
mice from Taconic) and C57Bl/6J strains (6 and 40 wk old mice from Jackson Labs) 
were sacrificed by cervical dislocation. SW and C57 mice of 52 wks of age were 
purchased from Taconic and Jackson Labs, respectively, and aged in our facility. All 
mice were maintained with free access to food and water, but without environmental 
enrichment [21].  Upon sacrifice, kidneys and brain were immediately removed and 
placed into 1 ml of ice-cold 50 mM Tris-HCl, pH 7.4.  The tissue was homogenized by 
30 strokes in a dounce homogenizer and sonicated (BranSonic sonifier) on ice for 15 sec 
(2x).  The homogenates were transferred to a sterile microcentrifuge tube for 
centrifugation at 10,000 x g at 4o C for 15 min to remove cell debris and nuclei.  These 
samples were transferred to another sterile microcentrifuge tube, and the centrifugation 
was repeated.  Final protein concentrations were determined using the BioRad® protein 
assay kit (Hercules, CA, USA), utilizing bovine serum albumin as the standard.  The 
brain and kidney homogenates were stored at -80º until use.  
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NEP activity 
Mouse tissue homogenates of brain or kidney and a standard curve of rhNEP (5 ng/ml – 5 
µg/ml) were pre-incubated with enalapril, an angiotensin-converting enzyme (ACE) 
inhibitor, for 30 minutes at 37ºC to prevent fluorogenic substrate (N-dansyl-D-Ala-Gly-p-
nitro-Phe-Gly) cleavage by ACE [20], in the presence or absence of phosphoramidon, a 
specific NEP inhibitor.  Following this pre-incubation, the fluorogenic substrate was 
added, and samples were incubated for an additional 1-2 hours at 37ºC.  The final 
concentrations were 12.5 µM for enalapril, 12.5 µM for phosphoramidon, and 500 µM 
for the substrate, in a reaction volume of 100 µl.  At each indicated time point, 
fluorescence absorbance was recorded using a Perkin-Elmer Victor3 Reader (Forster City, 
CA, USA) with an emission wavelength of 535 nm and an excitation wavelength of 355 
nm.  Arbitrary fluorescence units for each sample were compared with a standard curve 
prepared using rhNEP in order to determine the NEP specific activity per mg protein. 
 
Statistical Analyses 
Analysis of variance (2-way ANOVA) was used to compare NEP specific activity in SW 
mice across ages and genders for both brain and kidney samples, and across age and 
strain (SW and C57B/6J).  For all analyses, the confidence limit was set at p< 0.05.  
When a significant difference was determined by the 2-way ANOVA, an analysis of 
variance (1-way ANOVA) or Student’s t-test (confidence limits of p< 0.05) was also 
performed.  All statistical analyses were performed using Prism® 3.0 software.  The data 
are presented as means ± SEM. 
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RESULTS 
 
 
rh Neprilysin Standardization 
 
 
The activity of recombinant human neprilsyin (rhNEP) was determined at 4 
concentrations (0.005, 0.05, 0.5 and 5 µg/ml; n=3) following incubation for 1, 2 and 4 
hours in the absence or presence of phosphoramidon, a specific NEP inhibitor.  At the 
lowest concentration, 0.005 µg/ml (5 ng/ml), NEP activity was undetectable. As the 
concentration of rhNEP was increased, the amount of NEP activity increased in a 
concentration-dependent manner, as indicated by an increase in fluorometric emission.  
Further, NEP activity displayed a time dependency at the 0.5 µg/µl concentration.  
Phosphoramidon blocked the activity of rhNEP at all concentrations and times of 
incubation (data not shown).   
 
Neprilysin activity in kidney and brain as a function of age, gender and strain  
 
a) Kidney 
 
NEP activity was assayed in the kidney of young (6 wk), old (40 wk) and aged (80 wk) 
male and female SW mice (Fig 1A).  Kidney homogenate from female SW mice 
displayed a neprilysin specific activity (sp act) equivalent to 6.35 ± 0.29 ng rhNEP/mg of 
kidney protein.  In male SW mice, the neprilysin activity was equivalent to 2.51 ± 0.21 
ng rhNEP/mg kidney protein.  A two-way ANOVA demonstrated that kidney neprilysin 
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specific activity varied significantly according to gender (p < 0.0001; Fig 1A) but was not 
apparently altered with aging from 6 to 80 wk of age (p = 0.85).  
 
We also sought to determine whether kidney NEP specific activity varied according to 
background mouse strain.  NEP specific activity was assayed in kidney homogenates of 
male mice from the two strains (SW and C57Bl/6J, n = 5) at two ages (6 and 40 weeks) 
Kidney NEP specific activity was significantly different between these mouse strains 
(ANOVA two-way, p < 0.05). SW displayed higher specific activity (2.68 ± 0.23 ng 
rhNEP/mg kidney protein) compared to C57Bl/6J (2.05± 0.13 ng/mg kidney protein) 
(ANOVA one-way, p < 0.05; C57Bl/6J vs SW).  Neither strain showed an effect of aging 
on kidney NEP specific activity (Fig 1B). 
 
b)  Brain  
 
In contrast to kidney, brain NEP specific activity in SW mice did not vary according to 
gender but rather varied in both genders according to age (ANOVA two-way; age, p = 
0.0001; gender, p = 0.53) (Fig 2A). NEP specific activity at 80 weeks was significantly 
(~75%) reduced in both males and females relative to 6 weeks (one-way ANOVA, p < 
0.0002).  NEP specific activity in brain was also significantly different as a function of  
background mouse strain (ANOVA two-way, p < 0.001) (Fig 2B).  In the male mouse 
brain, NEP specific activity was significantly lower in the C57Bl/6J strain when 
compared to activity in the SW mouse brain at the ages of both 6 and 40 weeks. By the 
age of 80 weeks, however, both strains displayed a significant decrease in NEP specific 
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activity, such that activities between the two strains was no longer significantly different. 
A two-way ANOVA indicated that both age (p<0.0001) and strain (p<0.01) affected NEP 
specific activity. Furthermore, a one-way ANOVA analysis within strains showed that at 
the age of 80 weeks, NEP specific activity was significantly different compared to the 
activity at ages of 6 or 40 weeks (SW p<0.01; C57 p<0.01 and p<0.05. Fig. 2B). 
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DISCUSSION 
 
In humans, the propensity toward cerebral amyloidosis varies according to gender, 
genetic background, organ, and aging.  In the current study, we sought to test in mice the 
hypothesis that endogenous alterations in tissue NEP specific activity might be 
modulated by aging, gender or strain, and that modulation of NEP specific activity as a 
function of these variables might contribute to differential brain Aβ deposition following 
overexpression of human APP in transgenic mice.  As reviewed below, it is worth noting 
that data already exist that implicate the mouse background strain and aging in 
modulating the relative propensity toward Aβ accumulation.  
 
Role of genetic background in specifying the propensity toward cerebral Aβ amyloidosis  
 
Unsurprisingly, the various Aβ plaque-forming mice reported in the literature have been 
created in a variety of genetic background strains.  Of these, the only line containing the 
Swiss-Webster strain background is the PDAPP mouse, which is SW X C57Bl/6J X DBA 
and expresses APP at approximately 10-fold relative to endogenous levels [19].  Despite 
such exceptional levels of APP holoprotein expression, Aβ deposition occurs in only 
50% of the animals despite identical transgene dose. PDAPP mice that fail to develop Aβ 
plaques are designated “low pathology” mice [7], a heritable trait that might plausibly be 
attributable to the SW and/or DBA components of the background strain.  Our lab’s 
experience is consistent with this formulation. We created a line of APPSWE SW mice that 
demonstrated a 5-fold overexpression of the APP transgene relative to endogenous APP 
levels.  This level of APP fold-increase is clearly associated with plaque accumulation in 
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C57Bl/6J mice in other labs [2], yet our APPSWE SW mice demonstrated no plaque 
accumulation, even at 24 months of age, and even after back-crossing with C57Bl/6J for 
one or two generations (Gandy and Ehrlich, unpublished data).   
 
In recent work, Lamb and colleagues have proposed that the propensity toward 
Aβ deposition is at least partially controlled by genetic background [23].  In their studies, 
the Lamb group showed that YAC-APP transgenic mice on a congenic C57Bl/6J 
background showed Aβ plaque deposition as early as age 13 months, while YAC-APP 
transgenic mice on the DBA/2J background failed to produce plaques despite an identical 
level of overexpressed mutant APP [23].  
 
Role of gender in specifying the propensity toward cerebral Aβ amyloidosis 
 
Gender-related differences in plaque deposition in transgenic mice are also well 
recognized [e.g., 22]. Female APPSWE transgenic mice generated in a mixed strain 
background (C57Bl/6 X SJL) demonstrate greater amyloid deposition than do their male 
littermates, and this becomes more apparent with age [4, 22, 34]. In the current study, 
gender differences were examined only in the SW strain, and we observed that female 
kidney NEP specific activity was significantly higher than corresponding male kidney 
NEP specific activity; however, NEP specific activity was similar in males and females in 
the brains of these same animals.  Follow-up studies of the effect of estrogen and 
testosterone on NEP specific activity are underway since other studies along this line 
suggest that hormones are important regulators of NEP activity [14].  
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Role of aging in specifying the propensity toward cerebral Aβ amyloidosis 
 
In SW mice, and to a lesser extent in C57Bl/6J mice, we found that brain NEP specific 
activity is dramatically diminished in the aged brain, implying that this is not a strain-
specific occurrence.  These results agree with other studies that reported an aging-
dependent diminution in brain NEP activity [3, 18]. In C57Bl/6 male mice, NEP specific 
activity and protein levels are reported to decrease in the hippocampus by 20% over the 
lifespan from 10 to 132 weeks, while a much smaller decrease can be demonstrated in the 
neocortex [18]. In a mixed C57Bl6/129 background, neprilysin protein levels are reported 
to decrease by greater than 50% in the hippocampus between 2 and 18 (78 weeks) 
months [3]. Of note, however, the decrease in C57Bl/6J was far greater than that shown 
in the study by Iwata et al. [18], implying that there may be differences between sub-
strains of C57Bl, and/or that the differences in the total brain may be greater than in the 
hippocampus alone. The latter formulation appears unlikely, however, based on the 
correlation between our results and those from LaFerla and colleagues [3].  
 
Cerebral Aβ clearance and the role of neprilysin 
 
The literature supports the hypothesis that there might plausibly be direct links between 
levels of NEP activity and that of Aβ pathology.  For example, injection of a lentivirus 
expressing the NEP gene decreased AD pathology in plaque-forming PDAPP and 
TASD41 transgenic mice [25, 26].  The inhibitors of NEP, thiorphan and 
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phosphoramidon, were shown to block the proteolyzing activity of brain derived NEP on 
3H/14C Aβ1-42 peptide [12]. When transgenic mice overexpressing NEP are crossed with 
plaque forming mice, brain Aβ levels and plaque deposition both decrease [24].  
 
Despite recent advances in defining the role of NEP in cerebral Aβ clearance, the 
molecular and cellular mechanisms underlying clearance of brain Aβ are incompletely 
understood.  Both Aβ1-40 and Aβ1-42 are cleared rapidly from the blood and localized to 
the liver, spleen, kidney, urine, and stomach [11] with the liver accounting for 60% of Aβ 
concentration [12]. Therefore, reductions in NEP specific activity in the periphery may 
also play a role in the accumulation of soluble Aβ in AD brains by shifting the 
concentration gradient away from the circulation and toward brain absorption and 
subsequent plaque deposition.   The “peripheral sink” phenomenon associated with Aβ 
immunotherapy [7] dovetails well with such a concept, and the apparent success of that 
strategy in mouse models supports the notion that concomitant augmentation of both 
peripheral and central Aβ clearance may be an attractive approach to treatment or 
prevention of cerebral amyloidosis in AD. 
 
Conclusions 
 
In summary, we have investigated the role of background mouse strain, gender, and aging 
on the specific activity of NEP in two tissues.  Among the variables tested, NEP specific 
activity varied most dramatically across mouse strain, with the highest activities being 
observed in the kidney and brain of SW mice.  Aging was associated with a reduction in 
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brain NEP specific activity in both strains.  We conclude that aging- and strain-dependent 
differences in NEP specific activity may explain, at least in part, the roles that aging and 
background mouse strain play in differential specification of the susceptibility toward the 
development of cerebral Aβ amyloidosis. 
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FIGURE LEGENDS 
 
Fig 1.: Kidney NEP as a function of gender, aging, and mouse strain. 
A) Neprilysin specific activity is higher in female than in male, but independent from age 
(ANOVA two-way, p=0.85 for age, p<0.0001 for gender). Samples evaluated for gender 
only (Student’s t-test * p<0.0001). The data are expressed as mean ± SEM ng/mg kidney 
protein.  B) Neprilysin activity in males of 2 different strains: Swiss Webster and C57/6J 
(ANOVA two-way, p=0.39 for age, p<0.05 for strain). Samples from A evaluated for 
strain only (Student’s t-test * p<0.05).  The rhNEP specific activity is expressed as mean 
± SEM ng/mg kidney protein. 
 
Fig 2.: Brain NEP in SW mice as a function of gender, aging and mouse strain. 
A) Neprilysin activity does not differ in Swiss Webster female or male but decreases with 
age (ANOVA two-way, p<0.0001 for age, p=0.53 for gender). Samples evaluated for age 
only (ANOVA One-way * p<0.01, ** p<0.001). The rhNEP specific activity is expressed 
as mean ± SEM pg/mg brain protein. B) Neprilysin activity in males of 2 different 
strains: Swiss Webster and C57/6J (ANOVA two-way, p<0.0001 for age, p<0.01 for 
strain). Samples evaluated for one strain only (ANOVA One-way: p<0.001 for SW, 
p<0.01 for C57. Bonferroni analysis: * p<0.01, ** p<0.05). The rhNEP specific activity 
is expressed as mean ± SEM pg/mg brain protein. 
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